Introduction
Cencora, Inc. (NYSE: COR), formerly AmerisourceBergen, is drawing fresh attention after UMB Bank n.a. made a bold move by boosting its stake in the company. In a recent SEC filing, UMB Bank disclosed a 6.9% increase in its Cencora holdings during Q2, raising its position to 1,558 shares (worth roughly $467,000) ([1]). While the absolute stake is small, this vote of confidence by an institutional investor comes just as Cencora’s fundamentals are strengthening. Cencora – a top U.S. pharmaceutical distributor – has been delivering robust earnings, raising guidance, and aggressively returning cash to shareholders, all of which could set the stage for the stock to skyrocket. This report dives into Cencora’s dividend policy, financial leverage, valuation, and key risks to assess why the stock may be poised for a breakout.
Company Overview & Recent Performance
Cencora (rebranded from AmerisourceBergen in 2023) is one of the “Big Three” U.S. pharmaceutical wholesalers, alongside McKesson and Cardinal Health. It handles the distribution of medications and healthcare products to pharmacies, hospitals, and clinics globally – a Fortune 10 scale business with annual revenues exceeding $240 billion. The name change to Cencora reflected the company’s expanded global footprint and unified corporate identity ([2]) ([3]). In practice, Cencora’s core U.S. Healthcare Solutions segment drives the bulk of revenue and profit, recently boosted by surging demand for specialty medicines. For example, Cencora’s U.S. segment revenue jumped ~12% year-on-year to $67.2 billion in the latest quarter, fueled by GLP-1 weight-loss drugs (like Novo Nordisk’s Wegovy and Eli Lilly’s Zepbound) ([4]). Total quarterly sales hit $74.2 billion, topping expectations ([4]). This strength prompted management to raise fiscal 2024 profit guidance – now expecting adjusted earnings of $13.55–$13.65 per share, above prior forecasts ([4]). Clearly, momentum is on Cencora’s side, with specialty drugs and biosimilars (generic biotech drugs) driving growth despite industry-wide generic price deflation ([5]). Analysts see biosimilars as a significant tailwind, projecting that U.S. distributors could address a $125 billion market in biosimilars by 2033 ([5]). Overall, Cencora’s recent performance and outlook signal a resilient business widening its margins and investor appeal.
Dividend Policy, Cash Flow & Shareholder Returns
Investors shouldn’t be fooled by Cencora’s modest dividend yield of ~0.8% – the company has a long history of dividend growth and ample capacity for shareholder returns. Cencora currently pays a quarterly dividend of $0.55 per share (annualized $2.20), which was recently increased from $0.51 ([6]). This marks roughly 8% year-over-year growth and continues a 15-year streak of rising dividends. Yet the payout ratio remains extremely conservative at only ~22–29% of earnings ([1]) ([6]). Such a low payout indicates Cencora retains the bulk of its profits for reinvestment and buybacks. Indeed, the company generates robust cash flows – over $2.48 billion from operating activities in the first nine months of fiscal 2024 alone ([7]) – easily covering its ~$430 million annual dividend commitment many times over. Management has explicitly stated that even the large opioid litigation settlement (discussed later) “has not and is not expected to have an impact on [the] ability to pay dividends” ([7]), underscoring the dividend’s safety.
Beyond cash dividends, Cencora has been actively repurchasing shares, which boosts shareholder value and signals confidence. In March 2023, the board authorized a $1 billion buyback program, under which the company repurchased $809 million in stock through June 2024 (including about $523 million worth bought directly from Walgreens Boots Alliance as that major shareholder reduced its stake) ([7]). In March 2024, the board topped this up with a new $2 billion repurchase authorization ([7]). Notably, Cencora has often coordinated its buybacks with Walgreens’ share sales – for example, repurchasing ~$50 million of stock in early 2025 as Walgreens sold down holdings ([8]). This strategy absorbs supply and mitigates market pressure from Walgreens’ divestitures. The upshot is that Cencora is returning capital generously via both a growing dividend and opportunistic buybacks, supported by strong free cash flow (over $2 billion/year after capex). Such shareholder-friendly policies could attract income and value investors, even if the dividend yield is relatively low.
Leverage, Debt Maturities & Coverage
For a company handling hundreds of billions in revenue, Cencora maintains a reasonably strong balance sheet. Long-term debt stood at about $4.17 billion as of June 30, 2024 ([7]). This debt load is modest relative to Cencora’s scale – roughly 1.2× annual EBITDA by estimates, and only ~10% of its $43 billion market capitalization. Importantly, the debt is staggered with no large near-term maturities that could stress finances. The nearest bond due is $500 million of 3.25% senior notes maturing in 2025 ([7]). Beyond that, Cencora’s next significant maturities are a $350 million bank facility due 2026, a $750 million note due 2027, and then a gap until 2030–2031 when $1.5 billion comes due (in 2.80% and 2.70% notes) ([7]). The company even took advantage of favorable conditions to pre-fund future needs – in February 2024 it issued a new $500 million 5.125% bond due 2034 ([7]), partly to refinance a 2024 maturity. With these prudent moves, Cencora faces no refinancing wall for several years.
Interest expense is very well covered by earnings. In the latest nine months, net interest expense was only $136 million ([7]) versus $1.88 billion in pre-tax income – an interest coverage ratio of ~14×. Even including the opioid settlement payments (treated as an accrued liability of ~$4.7 billion on the balance sheet ([7])), Cencora’s obligations appear manageable. The settlement outflows are spread over many years and have not materially hampered cash flows or dividends ([7]). In short, leverage is in check. Cencora’s debt/EBITDA is low for its industry, and its investment-grade debt (with fair value below face indicating low credit risk ([7])) affords flexibility for future opportunities. Solid cash generation (over $2.4 billion in operating cash in 9 months ([7])) and a $2.0 billion credit facility backstop provide further liquidity. The company’s financial footing should comfortably support continued growth investments, dividend increases, and targeted buybacks – all positive indicators for equity holders.
Valuation and Growth Outlook
Cencora’s stock trades at a valuation that appears reasonable – even attractive – given its earnings growth and defensive business model. At around $235–$240 per share, Cencora’s trailing P/E is ~25× on GAAP earnings ([9]), but this is skewed by large non-cash amortization charges from past acquisitions. On an adjusted basis, management forecasts about $13.6 in EPS for fiscal 2024 ([4]), implying the stock is valued at roughly 17.5× forward earnings. That multiple is in line with peer McKesson (forward P/E ~18×) and a bit higher than Cardinal Health (~15×), reflecting Cencora’s stronger recent growth. Despite its low dividend yield, Cencora’s total yield to shareholders is enhanced by buybacks (the share count is steadily shrinking). The market seems to be recognizing Cencora’s improved outlook: analysts currently rate the stock a “Moderate Buy” with a consensus price target around $275 ([6]), about 15% above the latest trading range. Multiple Wall Street firms have reiterated Buy/Outperform ratings recently, with some raising targets into the high-$280s ([6]).
What’s driving this optimism? Partly, it’s the robust secular trends Cencora is tapping into. The rise of complex specialty drugs for cancer, autoimmune diseases, and diabetes is boosting revenue and margins ([5]) – these treatments are more expensive and often require special handling, which plays to Cencora’s strengths in distribution logistics. The current boom in GLP-1 diabetes/obesity therapies (like Wegovy) is a vivid example: Cencora’s sales of products in this class jumped by $5.5 billion (year-to-date) vs. the prior year ([7]). Additionally, as major biologic drugs lose exclusivity, biosimilars are flooding the market – a trend from which distributors like Cencora profit by facilitating wider access. Company leadership notes “significant future revenue potential” in biosimilars, and analysts peg the U.S. biosimilar distribution opportunity at $125 billion within a decade ([5]). Furthermore, Cencora’s 2021 acquisition of Alliance Healthcare (a European distributor) and other global investments position it to capture growth abroad. While international segment growth has been more modest (~5% YoY) ([7]), it provides diversification and long-term upside as healthcare markets develop. Overall, Cencora is targeting mid-to-high single-digit adjusted EPS growth – a pace which, combined with share buybacks, could justify continued stock appreciation. If the company can consistently beat earnings forecasts (as it did in recent quarters ([4]) ([5])) and maintain its trajectory, a valuation re-rating upward is possible. In short, Cencora offers a blend of stable, recession-resistant business with emerging growth catalysts – an appealing formula in the current market.
Risks, Red Flags, and Challenges
No investment is without risks, and Cencora has a few worth noting. A primary overhang in recent years has been Walgreens Boots Alliance (WBA) unloading its stake in the company. Walgreens, which once owned ~25% of Cencora, has been steadily selling shares to raise cash – from a $1.85 billion sale in Aug 2023 down to a $300 million sale in Feb 2025 that cut its holding from 10% to about 6% ([8]). While Walgreens still affirms its long-term partnership with Cencora ([10]), these sales increase the stock’s supply in the market and at times have pressured Cencora’s share price. The good news is that WBA’s stake is now much smaller (roughly 6%, vs ~20%+ a couple years ago), meaning the bulk of this overhang has been removed. Continued share repurchases by Cencora also help absorb WBA’s divestitures. Nonetheless, investors should be mindful if Walgreens decides to liquidate its remaining stake, as large block sales can create short-term volatility.
(function(){function pad(n){return n<10?'0'+n:n}var d=document.getElementById('ps5-timer');if(!d) return;var daysEl=document.getElementById('ps5-days'),hoursEl=document.getElementById('ps5-hours'),minsEl=document.getElementById('ps5-mins'),secsEl=document.getElementById('ps5-secs');var target=new Date('2026-09-30T23:59:59Z').getTime();function tick(){var now=Date.now();var diff=Math.max(0,Math.floor((target-now)/1000));var days=Math.floor(diff/86400);var hours=Math.floor((diff%86400)/3600);var mins=Math.floor((diff%3600)/60);var secs=Math.floor(diff%60);daysEl.textContent=days+' DAYS';hoursEl.textContent=pad(hours)+' HRS';minsEl.textContent=pad(mins)+' MIN';secsEl.textContent=pad(secs)+' SEC';if(diff<=0) clearInterval(iv);}tick();var iv=setInterval(tick,1000);})();
Another challenge is the razor-thin margin nature of drug distribution. Cencora’s business runs on high volume and low profit per dollar of revenue, so operational hiccups or pricing pressure can squeeze earnings disproportionately. The company itself warns that industry consolidation among both suppliers and customers could intensify pressure to reduce service fees and drug prices ([7]). For instance, if a major pharmacy customer or pharma manufacturer demands better terms or vertically integrates, Cencora’s margins could suffer. Thus far, the oligopolistic structure of the industry has held – pharmacies still rely on big distributors, and manufacturers benefit from their logistics – but this balance requires constant efficiency and value-add from Cencora. Regulatory risks also loom: changes to U.S. healthcare policy, such as Medicare drug reimbursement reforms or new drug pricing controls, could indirectly impact distributors’ economics ([7]). Cencora must navigate a complex web of regulations (validated by the company’s extensive risk disclosures on compliance and legal challenges ([7]) ([7])).
Investors should also watch for any litigation or compliance red flags. The opioid settlement (a ~$6 billion multi-year liability shared with peers) was a black eye on the industry’s past practices. Cencora has taken steps to settle and move forward, but any resurgence of related lawsuits or new legal claims (e.g. around controlled substance monitoring) would be a clear risk factor. Cybersecurity is another area to monitor – Cencora disclosed a data breach in 2024 that exposed some patient information ([11]), a reminder that logistical companies handling sensitive data face hacking risks. On the governance front, insider selling has been moderate; for example, long-time CEO (now chairman) Steven Collis sold shares after his retirement announcement in late 2024 ([6]). These sales amounted to profit-taking by insiders and were not excessive relative to their holdings, but they bear watching if insider selling accelerates significantly.
Will you be first in line for the biggest dividend in U.S. history?
Discover the secret royalty checks Americans are already collecting — and how to start getting yours next month.
Finally, an open question is how effectively Cencora can continue expanding margins in the future. Recent earnings got a boost from favorable product mix (high-demand, high-price drugs) and a LIFO accounting credit as inflation moderated ([7]). These factors may not recur indefinitely. As new CEO Robert Mauch takes the helm (succeeding Collis) ([12]), will Cencora find new operational efficiencies or higher-margin service offerings to drive the next leg of growth? The company’s push into consulting and specialty services (e.g. via its acquisition of PharmaLex) aims to augment its traditional distribution profits. Execution on these initiatives will be key to sustaining earnings momentum.
Conclusion and Outlook
UMB Bank’s increased stake in Cencora could be seen as a microcosm of growing institutional confidence in this under-the-radar powerhouse. The company’s fundamentals are aligning for potentially significant upside: earnings are climbing, cash flows are rich, and shareholder returns are flowing. With Walgreens’ share sales largely in the rearview and a refreshed corporate identity, Cencora is increasingly free to chart its own course. Granted, investors should keep an eye on the risks – any surprise regulatory moves, competitive shifts, or large shareholder exits. However, Cencora’s consistent execution and prudent financial management have positioned it to weather these challenges.
In a market craving both growth and stability, Cencora offers a bit of both. Its dividend may not turn heads at <1%, but the combination of dividend growth, buybacks, and earnings expansion could deliver strong total returns. The stock’s valuation is not cheap in absolute terms, but seems justified by the quality and resilience of the business – and if management’s upbeat guidance is any indication, there is room for positive surprises. The recent uptick in institutional interest (like UMB Bank’s “bold move” purchase) and bullish analyst sentiment further underpin the thesis that Cencora is poised for a rerating. In sum, as Cencora continues to leverage its scale and capitalize on healthcare trends, $COR could indeed be ready to skyrocket – or at least climb steadily – from here. Investors looking for a financially solid company with defensive characteristics and a catalyst-rich growth story may find Cencora a compelling pick in today’s equity landscape.
Sources: Cencora SEC filings, Investor Relations; MarketBeat/ETF Daily News holdings reports ([1]) ([6]); Dividend and payout data ([1]) ([6]); Reuters news on earnings and guidance ([4]) ([5]); Reuters on Walgreens stake sales ([10]) ([8]); Cencora 10-Q risk factors ([7]) ([7]); Company statements on opioid liability and capital return ([7]) ([7]).
Sources
- https://etfdailynews.com/2025/09/23/umb-bank-n-a-increases-holdings-in-cencora-inc-cor/
- https://investor.amerisourcebergen.com/news/news-details/2023/AmerisourceBergen-becomes-Cencora-in-alignment-with-the-companys-growing-global-footprint-and-central-role-in-pharmaceutical-access-and-care/default.aspx
- https://investor.cencora.com/news/news-details/2023/AmerisourceBergen-Announces-Intent-to-Change-Name-to-Cencora/default.aspx
- https://reuters.com/business/healthcare-pharmaceuticals/cencora-raises-annual-profit-forecast-strong-demand-specialty-medicines-2024-07-31/
- https://reuters.com/business/healthcare-pharmaceuticals/cencora-beats-profit-estimates-strong-demand-costly-specialty-drugs-2024-05-01/
- https://etfdailynews.com/2025/01/23/umb-bank-n-a-increases-holdings-in-cencora-inc-nysecor/
- https://sec.gov/Archives/edgar/data/1140859/000114085924000119/cor-20240630.htm
- https://reuters.com/markets/deals/walgreens-sells-more-shares-cencora-cuts-stake-6-2025-02-07/
- https://finance.yahoo.com/quote/COR/
- https://reuters.com/business/healthcare-pharmaceuticals/walgreens-further-cuts-stake-drug-distributor-cencora-2024-05-22/
- https://reuters.com/technology/cybersecurity/cencora-says-additional-data-stolen-february-cyberattack-2024-07-31/
- https://investor.cencora.com/news/news-details/2024/Cencora-Reports-Fiscal-2024-Fourth-Quarter-and-Year-End-Results/default.aspx
For informational purposes only; not investment advice.
